SCHEMBL24936243

SCHEMBL24936243

COc1cncc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 19/20 1.00
KCNH2 Q12809 19/20 1.00
NUAK1 O60285 1/20 0.81
CHEK2 O96017 1/20 0.81
RPS6KB1 P23443 1/20 0.81
FLT3 P36888 1/20 0.81
BLK P51451 1/20 0.81
PRKAG1 P54619 1/20 0.81
PRKAA1 Q13131 1/20 0.81
PRKAB1 Q9Y478 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29632362 1.00 CHEK1 (1.00) CHEK1KCNH2NUAK1CHEK2RPS6KB1
SCHEMBL24935546 0.91 KCNH2 (1.00) CHEK1KCNH2NUAK1CHEK2RPS6KB1
SCHEMBL29632320 0.91 KCNH2 (1.00) CHEK1KCNH2NUAK1CHEK2RPS6KB1
Prexasertib SCHEMBL30528862 0.90 CHEK1 (1.00) CHEK1KCNH2NUAK1CHEK2RPS6KB1
SCHEMBL19208017 0.90 CHEK1 (0.81) CHEK1KCNH2NUAK1CHEK2RPS6KB1
Prexasertib SCHEMBL30517001 0.90 CHEK1 (1.00) CHEK1KCNH2NUAK1CHEK2RPS6KB1
Prexasertib SCHEMBL29371799 0.90 CHEK1 (1.00) CHEK1KCNH2NUAK1CHEK2RPS6KB1
SCHEMBL23327317 0.90 CHEK1 (0.81) CHEK1KCNH2NUAK1CHEK2RPS6KB1
Prexasertib SCHEMBL1975451 0.90 CHEK1 (1.00) CHEK1KCNH2NUAK1CHEK2RPS6KB1
SCHEMBL19208028 0.90 CHEK1 (0.81) CHEK1KCNH2NUAK1CHEK2RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022109-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2026-01-22 US claimed
US-20250352541-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR Sumitomo Pharma Co., Ltd. (JP) 2025-11-20 US claimed
US-12410154-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2025-09-09 US claimed
EP-4534100-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR Sumitomo Pharma Co., Ltd. (JP) 2025-04-09 EP claimed
WO-2023229032-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR 住友ファーマ株式会社 2023-11-30 WO claimed
EP-4253377-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-10-04 EP claimed
CN-116546974-A 5-heteroaryl-1H-pyrazol-3-amine derivatives 住友制药株式会社 2023-08-04 CN claimed
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2023-01-31 US claimed
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-01-26 US claimed
US-20220273649-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2022-09-01 US claimed
US-20260022109-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2026-01-22 US disclosed
US-20250352541-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR Sumitomo Pharma Co., Ltd. (JP) 2025-11-20 US disclosed
US-12410154-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2025-09-09 US disclosed
EP-4534100-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR Sumitomo Pharma Co., Ltd. (JP) 2025-04-09 EP disclosed
WO-2023229032-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR 住友ファーマ株式会社 2023-11-30 WO disclosed
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2023-01-31 US disclosed
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative Sumitomo Pharma Co., Ltd. (JP) 2023-01-31 US disclosed
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-01-26 US disclosed
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-01-26 US disclosed
US-20220273649-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2022-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11564920-B2 5-heteroaryl-1H-pyrazol-3-amine derivative CHEK1, CHEK2, RB1 CHEK1 1/4885KCNH2 2700/4885NUAK1 124/4885
US-20230025065-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE CHEK1, CHEK2, RB1 CHEK1 1/4885KCNH2 2700/4885NUAK1 124/4885
US-20260022109-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE CHEK1, CHEK2, WEE1 CHEK1 1/4885KCNH2 1341/4885NUAK1 268/4885
US-20220273649-A1 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE CHEK1, CHEK2, RB1 CHEK1 1/4885KCNH2 2700/4885NUAK1 124/4885
US-12410154-B2 5-heteroaryl-1H-pyrazol-3-amine derivative CHEK1, CHEK2, RB1 CHEK1 1/4885KCNH2 2700/4885NUAK1 124/4885
US-20250352541-A1 THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR CHEK1, CHEK2, PDCD1 CHEK1 1/4885KCNH2 2395/4885NUAK1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.